How Amgen’s Larger-Than-Expected Dividend Hike Stacks Up to Peers
Amgen is getting aggressive enough on its dividend payout that you might think the biotech giant is now just a Big Pharma stock.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 233
Lakeland Stumbles on Mixed Earnings
Lakeland Industries reported mixed fiscal 2016 third-quarter financial results after the markets closed on Tuesday.
Pacira Pharma Soars on Settled FDA Case
Pacira Pharmaceuticals announced that it achieved an amicable resolution with the FDA for a lawsuit filed earlier this year that effectively lifts the restriction on its Exparel.
Why Neothetics Is Getting Destroyed
Neothetics Inc. (NASDAQ: NEOT) was absolutely crashed in Tuesday’s session after announcing top-line results from a late stage trial that fell short.
Spark Therapeutics Files for Secondary Offering
Spark Therapeutics has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for a secondary offering.
AcelRx Tanks on Pre-NDA Results
AcelRx intends to pursue an ARX-04 indication for moderate-to-severe pain in a medically supervised setting. However, this might be farther out than investors anticipated.
Quidel Seen as Good Bet on Flu Season Drugs
Quidel is considered a bet on flu season. The analyst team over at Canaccord Genuity likes Quidel quite a bit.
What Atara Bio Has Under the Hood After Kidney Drug Failure
Atara Biotherapeutics announced results from its Phase 2 proof-of-concept clinical trial for PINTA 745 for the treatment of protein energy wasting in patients with end stage renal disease.
Could This New Deal Double Akebia Therapeutics?
Akebia Therapeutics led the bulls early on Monday following news of what looks like a big commercialization partnership in Asia.
5 Key BioPharma Movers That Cannot Be Ignored
Bluebird Bio, Idera Pharmaceuticals and others stood out from other biotech stock with incredible gains or losses over the course of the past week.
Cara Therapeutics Posts Strong Phase 2 Results
Cara Therapeutics saw its stock rise in Wednesday’s session on statistically significant Phase 2 results, but the delight of investors may be short lived.
Short Interest in Major Pharma Takes a Giant Leap
The November 30 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was up.
Mixed Views on Major Biotech Short Interest
The November 30 short interest data have been compared with the previous report, and short interest was mixed in these selected stocks for this settlement date.
Baxalta Rises on FDA Approval
Baxalta was rising in Wednesday’s trading session on news of a key U.S. Food and Drug Administration (FDA) approval.
Aeterna Zentaris Prices Secondary Offering
Aeterna Zentaris has amended is filing with the U.S. Securities and Exchange Commission (SEC) for its secondary offering.